$MBVX Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in MABVAX THERAPEUTICS HOLDINGS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in MABVAX THERAPEUTICS HOLDINGS, INC.. Get notifications about new insider transactions in MABVAX THERAPEUTICS HOLDINGS, INC. for free.
Page: < prev 1 2 3 4 5 5 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jan 03 2017 | MBVX | MABVAX THERAPEUTIC ... | EISENBERG JEFFREY F | Option Exercise | A | 3.38 | 2,300 | 7,774 | 2,300 | ||
Jan 03 2017 | MBVX | MABVAX THERAPEUTIC ... | Ravetch Jeffrey V. | Option Exercise | A | 3.38 | 4,100 | 13,858 | 4,100 | ||
Jan 03 2017 | MBVX | MABVAX THERAPEUTIC ... | Varvaro Thomas C | Option Exercise | A | 3.38 | 3,800 | 12,844 | 3,800 | ||
Jan 03 2017 | MBVX | MABVAX THERAPEUTIC ... | MAIER PAUL V | Option Exercise | A | 3.38 | 4,100 | 13,858 | 4,100 | ||
Jan 03 2017 | MBVX | MABVAX THERAPEUTIC ... | Resnick Paul F | VICE PRESIDENT, CBO | Option Exercise | A | 3.38 | 15,200 | 51,376 | 15,200 | |
Jan 03 2017 | MBVX | MABVAX THERAPEUTIC ... | HOFFMAN ROBERT | Option Exercise | A | 3.38 | 4,100 | 13,858 | 4,100 | ||
Jan 03 2017 | MBVX | MABVAX THERAPEUTIC ... | Cohen Kenneth M | Option Exercise | A | 3.38 | 4,100 | 13,858 | 4,100 | ||
Jan 03 2017 | MBVX | MABVAX THERAPEUTIC ... | MAFFUID PAUL W | EXECUTIVE VICE PRES ... | Option Exercise | A | 3.38 | 20,100 | 67,938 | 20,100 | |
Jan 03 2017 | MBVX | MABVAX THERAPEUTIC ... | HANSON GREGORY P | CHIEF FINANCIAL OFF ... | Option Exercise | A | 3.38 | 26,400 | 89,232 | 26,400 | |
Jan 03 2017 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Option Exercise | A | 3.38 | 63,400 | 214,292 | 63,400 | |
Nov 04 2016 | MBVX | MABVAX THERAPEUTIC ... | Ravetch Jeffrey V. | Option Exercise | A | 3.75 | 17,500 | 65,625 | 17,500 | ||
Aug 30 2016 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Option Exercise | A | 5.00 | 63,400 | 317,000 | 63,400 | |
Aug 30 2016 | MBVX | MABVAX THERAPEUTIC ... | HANSON GREGORY P | CHIEF FINANCIAL OFF ... | Option Exercise | A | 5.00 | 26,400 | 132,000 | 26,400 | |
Aug 30 2016 | MBVX | MABVAX THERAPEUTIC ... | MAFFUID PAUL W | EXECUTIVE VICE PRES ... | Option Exercise | A | 5.00 | 20,100 | 100,500 | 20,100 | |
Aug 30 2016 | MBVX | MABVAX THERAPEUTIC ... | Resnick Paul F | VICE PRESIDENT, CBO | Option Exercise | A | 5.00 | 15,200 | 76,000 | 15,200 | |
Aug 30 2016 | MBVX | MABVAX THERAPEUTIC ... | Cohen Kenneth M | Option Exercise | A | 5.00 | 4,100 | 20,500 | 4,100 | ||
Aug 30 2016 | MBVX | MABVAX THERAPEUTIC ... | HOFFMAN ROBERT | Option Exercise | A | 5.00 | 4,100 | 20,500 | 4,100 | ||
Aug 30 2016 | MBVX | MABVAX THERAPEUTIC ... | MAIER PAUL V | Option Exercise | A | 5.00 | 4,100 | 20,500 | 4,100 | ||
Aug 30 2016 | MBVX | MABVAX THERAPEUTIC ... | Varvaro Thomas C | Option Exercise | A | 5.00 | 3,800 | 19,000 | 3,800 | ||
Aug 30 2016 | MBVX | MABVAX THERAPEUTIC ... | EISENBERG JEFFREY F | Option Exercise | A | 5.00 | 2,300 | 11,500 | 2,300 | ||
Aug 30 2016 | MBVX | MABVAX THERAPEUTIC ... | Livingston Philip O. | CHIEF SCIENCE OFFIC ... | Option Exercise | A | 5.00 | 700 | 3,500 | 700 | |
Aug 30 2016 | MBVX | MABVAX THERAPEUTIC ... | Ravetch Jeffrey V. | Option Exercise | A | 5.00 | 4,100 | 20,500 | 4,100 | ||
Aug 19 2016 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Option Exercise | P | 6.29 | 3,119 | 19,619 | 3,119 | |
Aug 19 2016 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Option Exercise | P | 5.55 | 3,119 | 17,310 | 3,119 | |
Aug 19 2016 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Buy | P | 0.00 | 3,119 | 0 | 37,529 | 34.4 K to 37.5 K (+9.06 %) |
Aug 19 2016 | MBVX | MABVAX THERAPEUTIC ... | HANSON GREGORY P | CHIEF FINANCIAL OFF ... | Option Exercise | P | 6.29 | 3,119 | 19,619 | 3,119 | |
Aug 19 2016 | MBVX | MABVAX THERAPEUTIC ... | HANSON GREGORY P | CHIEF FINANCIAL OFF ... | Option Exercise | P | 5.55 | 3,119 | 17,310 | 3,119 | |
Aug 19 2016 | MBVX | MABVAX THERAPEUTIC ... | HANSON GREGORY P | CHIEF FINANCIAL OFF ... | Buy | P | 0.00 | 3,119 | 0 | 16,744 | 13.6 K to 16.7 K (+22.89 %) |
Aug 19 2016 | MBVX | MABVAX THERAPEUTIC ... | MAFFUID PAUL W | EXECUTIVE VICE PRES ... | Option Exercise | P | 6.29 | 2,079 | 13,077 | 2,079 | |
Aug 19 2016 | MBVX | MABVAX THERAPEUTIC ... | MAFFUID PAUL W | EXECUTIVE VICE PRES ... | Option Exercise | P | 5.55 | 2,079 | 11,538 | 2,079 | |
Aug 19 2016 | MBVX | MABVAX THERAPEUTIC ... | MAFFUID PAUL W | EXECUTIVE VICE PRES ... | Buy | P | 0.00 | 2,079 | 0 | 12,267 | 10.2 K to 12.3 K (+20.41 %) |
Aug 19 2016 | MBVX | MABVAX THERAPEUTIC ... | Cohen Kenneth M | Option Exercise | P | 6.29 | 3,119 | 19,619 | 3,119 | ||
Aug 19 2016 | MBVX | MABVAX THERAPEUTIC ... | Cohen Kenneth M | Option Exercise | P | 5.55 | 3,119 | 17,310 | 3,119 | ||
Aug 19 2016 | MBVX | MABVAX THERAPEUTIC ... | Cohen Kenneth M | Buy | P | 0.00 | 3,119 | 0 | 6,014 | 2.9 K to 6 K (+107.74 %) | |
Jul 28 2016 | MBVX | MABVAX THERAPEUTIC ... | EISENBERG JEFFREY F | Option Exercise | A | 0.55 | 35,000 | 19,250 | 35,000 | ||
Jul 28 2016 | MBVX | MABVAX THERAPEUTIC ... | Varvaro Thomas C | Option Exercise | A | 0.55 | 35,000 | 19,250 | 35,000 | ||
Jul 28 2016 | MBVX | MABVAX THERAPEUTIC ... | Ravetch Jeffrey V. | Option Exercise | A | 0.55 | 35,000 | 19,250 | 35,000 | ||
Jul 28 2016 | MBVX | MABVAX THERAPEUTIC ... | HOFFMAN ROBERT | Option Exercise | A | 0.55 | 35,000 | 19,250 | 35,000 | ||
Jul 28 2016 | MBVX | MABVAX THERAPEUTIC ... | Cohen Kenneth M | Option Exercise | A | 0.55 | 35,000 | 19,250 | 35,000 | ||
Jul 28 2016 | MBVX | MABVAX THERAPEUTIC ... | MAIER PAUL V | Option Exercise | A | 0.55 | 35,000 | 19,250 | 35,000 | ||
Apr 05 2016 | MBVX | MABVAX THERAPEUTIC ... | Scholz Wolfgang W. | VP OF ANTIBODY DISC ... | Option Exercise | M | 0.00 | 101,584 | 0 | 203,166 | |
Apr 05 2016 | MBVX | MABVAX THERAPEUTIC ... | Scholz Wolfgang W. | VP OF ANTIBODY DISC ... | Payment of Exercise | F | 0.00 | 38,320 | 0 | 113,288 | 151.6 K to 113.3 K (-25.28 %) |
Apr 05 2016 | MBVX | MABVAX THERAPEUTIC ... | Scholz Wolfgang W. | VP OF ANTIBODY DISC ... | Buy | M | 0.00 | 101,584 | 0 | 151,608 | 50 K to 151.6 K (+203.07 %) |
Apr 05 2016 | MBVX | MABVAX THERAPEUTIC ... | HOFFMAN ROBERT | Option Exercise | M | 0.00 | 11,417 | 0 | 22,833 | ||
Apr 05 2016 | MBVX | MABVAX THERAPEUTIC ... | HOFFMAN ROBERT | Buy | M | 0.00 | 11,417 | 0 | 21,417 | 10 K to 21.4 K (+114.17 %) | |
Apr 05 2016 | MBVX | MABVAX THERAPEUTIC ... | Varvaro Thomas C | Option Exercise | M | 0.00 | 11,417 | 0 | 22,833 | ||
Apr 05 2016 | MBVX | MABVAX THERAPEUTIC ... | Varvaro Thomas C | Buy | M | 0.00 | 11,417 | 0 | 11,417 | 0 to 11.4 K | |
Apr 05 2016 | MBVX | MABVAX THERAPEUTIC ... | Ravetch Jeffrey V. | Option Exercise | M | 0.00 | 11,417 | 0 | 22,833 | ||
Apr 05 2016 | MBVX | MABVAX THERAPEUTIC ... | Ravetch Jeffrey V. | Buy | M | 0.00 | 11,417 | 0 | 11,417 | 0 to 11.4 K | |
Apr 05 2016 | MBVX | MABVAX THERAPEUTIC ... | MAIER PAUL V | Option Exercise | M | 0.00 | 11,417 | 0 | 22,833 | ||
Apr 05 2016 | MBVX | MABVAX THERAPEUTIC ... | MAIER PAUL V | Buy | M | 0.00 | 11,417 | 0 | 16,417 | 5 K to 16.4 K (+228.34 %) | |
Apr 05 2016 | MBVX | MABVAX THERAPEUTIC ... | Cohen Kenneth M | Option Exercise | M | 0.00 | 11,417 | 0 | 22,833 | ||
Apr 05 2016 | MBVX | MABVAX THERAPEUTIC ... | Cohen Kenneth M | Buy | M | 0.00 | 11,417 | 0 | 11,417 | 0 to 11.4 K | |
Apr 05 2016 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Option Exercise | M | 0.00 | 301,184 | 0 | 602,166 | |
Apr 05 2016 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Payment of Exercise | F | 0.00 | 113,148 | 0 | 254,634 | 367.8 K to 254.6 K (-30.76 %) |
Apr 05 2016 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Buy | M | 0.00 | 301,084 | 0 | 367,782 | 66.7 K to 367.8 K (+451.41 %) |
Apr 05 2016 | MBVX | MABVAX THERAPEUTIC ... | MAFFUID PAUL W | EXECUTIVE VICE PRES ... | Option Exercise | M | 0.00 | 111,334 | 0 | 222,666 | |
Apr 05 2016 | MBVX | MABVAX THERAPEUTIC ... | MAFFUID PAUL W | EXECUTIVE VICE PRES ... | Payment of Exercise | F | 0.00 | 40,944 | 0 | 75,390 | 116.3 K to 75.4 K (-35.20 %) |
Apr 05 2016 | MBVX | MABVAX THERAPEUTIC ... | MAFFUID PAUL W | EXECUTIVE VICE PRES ... | Buy | M | 0.00 | 111,334 | 0 | 116,334 | 5 K to 116.3 K (+2,226.68 %) |
Apr 05 2016 | MBVX | MABVAX THERAPEUTIC ... | HANSON GREGORY P | CHIEF FINANCIAL OFF ... | Option Exercise | M | 0.00 | 155,867 | 0 | 311,733 | |
Apr 05 2016 | MBVX | MABVAX THERAPEUTIC ... | HANSON GREGORY P | CHIEF FINANCIAL OFF ... | Payment of Exercise | F | 0.00 | 58,044 | 0 | 100,823 | 158.9 K to 100.8 K (-36.54 %) |
Apr 05 2016 | MBVX | MABVAX THERAPEUTIC ... | HANSON GREGORY P | CHIEF FINANCIAL OFF ... | Buy | M | 0.00 | 155,867 | 0 | 158,867 | 3 K to 158.9 K (+5,195.57 %) |
Mar 24 2016 | MBVX | MABVAX THERAPEUTIC ... | Ravetch Jeffrey V. | Sell | S | 0.60 | 131,500 | 78,900 | 0 | 131.5 K to 0 (-100.00 %) | |
Feb 18 2016 | MBVX | MABVAX THERAPEUTIC ... | Scholz Wolfgang W. | VP OF ANTIBODY DISC ... | Option Exercise | A | 0.49 | 60,000 | 29,400 | 60,000 | |
Feb 18 2016 | MBVX | MABVAX THERAPEUTIC ... | MAFFUID PAUL W | VICE PRESIDENT | Option Exercise | A | 0.49 | 60,000 | 29,400 | 60,000 | |
Feb 18 2016 | MBVX | MABVAX THERAPEUTIC ... | HANSON GREGORY P | CHIEF FINANCIAL OFF ... | Option Exercise | A | 0.49 | 20,000 | 9,800 | 20,000 | |
Feb 18 2016 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | PRESIDENT AND CEO | Option Exercise | A | 0.49 | 500,000 | 245,000 | 500,000 | |
Aug 27 2015 | MBVX | MABVAX THERAPEUTIC ... | Varvaro Thomas C | Option Exercise | A | 1.52 | 35,000 | 53,200 | 35,000 | ||
Aug 27 2015 | MBVX | MABVAX THERAPEUTIC ... | Ravetch Jeffrey V. | Option Exercise | A | 1.52 | 35,000 | 53,200 | 35,000 | ||
Aug 27 2015 | MBVX | MABVAX THERAPEUTIC ... | MAIER PAUL V | Option Exercise | A | 1.52 | 35,000 | 53,200 | 35,000 | ||
Aug 27 2015 | MBVX | MABVAX THERAPEUTIC ... | HOFFMAN ROBERT | Option Exercise | A | 1.52 | 35,000 | 53,200 | 35,000 | ||
Aug 27 2015 | MBVX | MABVAX THERAPEUTIC ... | Cohen Kenneth M | Option Exercise | A | 1.52 | 35,000 | 53,200 | 35,000 | ||
Jun 02 2015 | MBVX | MABVAX THERAPEUTIC ... | MAIER PAUL V | Buy | P | 2.30 | 5,000 | 11,500 | 5,000 | 0 to 5 K | |
May 26 2015 | MBVX | MABVAX THERAPEUTIC ... | Cohen Kenneth M | Buy | P | 2.30 | 3,500 | 8,050 | 10,000 | 6.5 K to 10 K (+53.85 %) | |
Apr 07 2015 | MBVX | MABVAX THERAPEUTIC ... | WICK MICHAEL M | Director | Grant | A | 0.00 | 20,000 | 0 | 33,551 | 13.6 K to 33.6 K (+147.59 %) |
Apr 07 2015 | MBVX | MABVAX THERAPEUTIC ... | Ravetch Jeffrey V. | Director | Grant | A | 0.00 | 131,500 | 0 | 131,500 | 0 to 131.5 K |
Apr 07 2015 | MBVX | MABVAX THERAPEUTIC ... | Livingston Philip O. | Chief Science Offic ... | Grant | A | 0.00 | 1,000,000 | 0 | 1,307,396 | 307.4 K to 1.3 M (+325.31 %) |
Apr 03 2015 | MBVX | MABVAX THERAPEUTIC ... | WICK MICHAEL M | Director | Option Exercise | A | 0.00 | 34,250 | 0 | 34,250 | |
Apr 03 2015 | MBVX | MABVAX THERAPEUTIC ... | WICK MICHAEL M | Director | Option Exercise | A | 2.30 | 34,250 | 78,775 | 34,250 | |
Apr 03 2015 | MBVX | MABVAX THERAPEUTIC ... | Scholz Wolfgang W. | VP of Antibody Disc ... | Option Exercise | A | 0.00 | 304,750 | 0 | 304,750 | |
Apr 03 2015 | MBVX | MABVAX THERAPEUTIC ... | Scholz Wolfgang W. | VP of Antibody Disc ... | Option Exercise | A | 2.30 | 304,750 | 700,925 | 304,750 | |
Apr 03 2015 | MBVX | MABVAX THERAPEUTIC ... | MAFFUID PAUL W | Vice President | Option Exercise | A | 0.00 | 334,000 | 0 | 334,000 | |
Apr 03 2015 | MBVX | MABVAX THERAPEUTIC ... | MAFFUID PAUL W | Vice President | Option Exercise | A | 2.30 | 334,000 | 768,200 | 334,000 | |
Apr 03 2015 | MBVX | MABVAX THERAPEUTIC ... | Ravetch Jeffrey V. | Director | Option Exercise | A | 0.00 | 34,250 | 0 | 34,250 | |
Apr 03 2015 | MBVX | MABVAX THERAPEUTIC ... | Ravetch Jeffrey V. | Director | Option Exercise | A | 2.30 | 34,250 | 78,775 | 34,250 | |
Apr 03 2015 | MBVX | MABVAX THERAPEUTIC ... | MAIER PAUL V | Director | Option Exercise | A | 0.00 | 34,250 | 0 | 34,250 | |
Apr 03 2015 | MBVX | MABVAX THERAPEUTIC ... | MAIER PAUL V | Director | Option Exercise | A | 2.30 | 34,250 | 78,775 | 34,250 | |
Apr 03 2015 | MBVX | MABVAX THERAPEUTIC ... | HOFFMAN ROBERT | Director | Option Exercise | A | 0.00 | 34,250 | 0 | 34,250 | |
Apr 03 2015 | MBVX | MABVAX THERAPEUTIC ... | HOFFMAN ROBERT | Director | Option Exercise | A | 2.30 | 34,250 | 78,775 | 34,250 | |
Apr 03 2015 | MBVX | MABVAX THERAPEUTIC ... | HANSON GREGORY P | Chief Financial Off ... | Option Exercise | A | 0.00 | 467,600 | 0 | 467,600 | |
Apr 03 2015 | MBVX | MABVAX THERAPEUTIC ... | HANSON GREGORY P | Chief Financial Off ... | Option Exercise | A | 2.30 | 467,600 | 1,075,480 | 467,600 | |
Apr 03 2015 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | President and CEO | Option Exercise | A | 0.00 | 903,250 | 0 | 903,250 | |
Apr 03 2015 | MBVX | MABVAX THERAPEUTIC ... | HANSEN JOHN DAVID | President and CEO | Option Exercise | A | 2.30 | 903,250 | 2,077,475 | 903,250 | |
Apr 03 2015 | MBVX | MABVAX THERAPEUTIC ... | Cohen Kenneth M | Director | Option Exercise | A | 0.00 | 34,250 | 0 | 34,250 | |
Apr 03 2015 | MBVX | MABVAX THERAPEUTIC ... | Cohen Kenneth M | Director | Option Exercise | A | 2.30 | 34,250 | 78,775 | 34,250 | |
Dec 18 2014 | MBVX | MABVAX THERAPEUTIC ... | Cohen Kenneth M | Director | Buy | P | 1.80 | 2,500 | 4,500 | 17,616 | 15.1 K to 17.6 K (+16.54 %) |
Dec 17 2014 | MBVX | MABVAX THERAPEUTIC ... | HANSON GREGORY P | Chief Financial Off ... | Buy | P | 2.50 | 3,000 | 7,500 | 3,000 | 0 to 3 K |
Dec 17 2014 | MBVX | MABVAX THERAPEUTIC ... | Cohen Kenneth M | Director | Buy | P | 2.41 | 4,000 | 9,640 | 15,116 | 11.1 K to 15.1 K (+35.98 %) |
Dec 17 2014 | MBVX | MABVAX THERAPEUTIC ... | HOFFMAN ROBERT | Director | Buy | P | 2.40 | 10,000 | 24,000 | 21,116 | 11.1 K to 21.1 K (+89.96 %) |
Sep 15 2014 | MBVX | MABVAX THERAPEUTIC ... | Antonopoulos Jim J. | Option Exercise | X | 3.62 | 33,150 | 120,003 | 0 | ||
Sep 15 2014 | MBVX | MABVAX THERAPEUTIC ... | Antonopoulos Jim J. | Sell | S | 6.00 | 11,892 | 71,352 | 21,258 | 33.2 K to 21.3 K (-35.87 %) | |
Sep 15 2014 | MBVX | MABVAX THERAPEUTIC ... | Antonopoulos Jim J. | Buy | X | 3.62 | 33,150 | 120,003 | 33,150 | 0 to 33.2 K | |
May 17 2013 | MBVX | MABVAX THERAPEUTIC ... | GOLDRING STEVEN R | Director | Option Exercise | A | 1.36 | 333 | 453 | 333 | |
May 17 2013 | MBVX | MABVAX THERAPEUTIC ... | NEWMAN RICHARD B | Director | Option Exercise | A | 1.36 | 333 | 453 | 333 | |
May 17 2013 | MBVX | MABVAX THERAPEUTIC ... | CANTRALL EDWARD W | Director | Option Exercise | A | 1.36 | 333 | 453 | 333 | |
Dec 19 2012 | MBVX | MABVAX THERAPEUTIC ... | Barry Richard | 10% Owner | Sell | S | 1.86 | 48,390 | 90,049 | 243,800 | 292.2 K to 243.8 K (-16.56 %) |
Dec 14 2012 | MBVX | MABVAX THERAPEUTIC ... | Barry Richard | 10% Owner | Sell | S | 2.31 | 40,920 | 94,664 | 292,200 | 333.1 K to 292.2 K (-12.28 %) |
Dec 14 2012 | MBVX | MABVAX THERAPEUTIC ... | Barry Richard | 10% Owner | Sell | S | 1.87 | 61,798 | 115,803 | 292,200 | 354 K to 292.2 K (-17.46 %) |
Apr 03 2012 | MBVX | MABVAX THERAPEUTIC ... | von Morze Herwig | Director | Option Exercise | A | 0.16 | 10,000 | 1,600 | 10,000 | |
Apr 03 2012 | MBVX | MABVAX THERAPEUTIC ... | GOLDRING STEVEN R | Director | Option Exercise | A | 0.16 | 10,000 | 1,600 | 10,000 | |
Apr 03 2012 | MBVX | MABVAX THERAPEUTIC ... | NEWMAN RICHARD B | Director | Option Exercise | A | 0.16 | 10,000 | 1,600 | 10,000 | |
Apr 03 2012 | MBVX | MABVAX THERAPEUTIC ... | CANTRALL EDWARD W | Director | Option Exercise | A | 0.16 | 10,000 | 1,600 | 10,000 | |
May 26 2011 | MBVX | MABVAX THERAPEUTIC ... | Steuer Marc | SVP - Business Deve ... | Option Exercise | A | 0.69 | 200,000 | 138,000 | 200,000 | |
May 25 2011 | MBVX | MABVAX THERAPEUTIC ... | Wee Wendy | VP, Finance & Contr ... | Option Exercise | A | 0.69 | 290,000 | 200,100 | 290,000 | |
May 25 2011 | MBVX | MABVAX THERAPEUTIC ... | Schow Steven R | Vice President, Res ... | Option Exercise | A | 0.69 | 225,000 | 155,250 | 225,000 | |
May 25 2011 | MBVX | MABVAX THERAPEUTIC ... | Kaplan William Phillip | VP, General Counsel ... | Option Exercise | A | 0.69 | 200,000 | 138,000 | 200,000 | |
May 25 2011 | MBVX | MABVAX THERAPEUTIC ... | WICK MICHAEL M | President, CEO and ... | Option Exercise | A | 0.69 | 350,000 | 241,500 | 350,000 | |
May 25 2011 | MBVX | MABVAX THERAPEUTIC ... | WICK MICHAEL M | President, CEO and ... | Option Exercise | A | 0.69 | 500,000 | 345,000 | 500,000 | |
May 23 2011 | MBVX | MABVAX THERAPEUTIC ... | von Morze Herwig | Director | Option Exercise | A | 0.67 | 10,000 | 6,700 | 10,000 | |
May 23 2011 | MBVX | MABVAX THERAPEUTIC ... | GOLDRING STEVEN R | Director | Option Exercise | A | 0.67 | 10,000 | 6,700 | 10,000 | |
May 23 2011 | MBVX | MABVAX THERAPEUTIC ... | NEWMAN RICHARD B | Director | Option Exercise | A | 0.67 | 10,000 | 6,700 | 10,000 | |
May 23 2011 | MBVX | MABVAX THERAPEUTIC ... | CANTRALL EDWARD W | Director | Option Exercise | A | 0.67 | 10,000 | 6,700 | 10,000 | |
Dec 15 2010 | MBVX | MABVAX THERAPEUTIC ... | Barry Richard J. | 10% Owner | Buy | J | 0.00 | 1,186,055 | 0 | 11,847,125 | 10.7 M to 11.8 M (+11.13 %) |
Aug 23 2010 | MBVX | MABVAX THERAPEUTIC ... | CANTRALL EDWARD W | Director | Buy | P | 0.72 | 6,000 | 4,320 | 50,000 | 44 K to 50 K (+13.64 %) |
Jun 21 2010 | MBVX | MABVAX THERAPEUTIC ... | Barry Richard J. | 10% Owner | Buy | P | 0.76 | 53,300 | 40,508 | 12,057,118 | 12 M to 12.1 M (+0.44 %) |
Jun 21 2010 | MBVX | MABVAX THERAPEUTIC ... | Barry Richard J. | 10% Owner | Buy | P | 0.73 | 4,400 | 3,212 | 12,003,818 | 12 M to 12 M (+0.04 %) |
Jun 24 2010 | MBVX | MABVAX THERAPEUTIC ... | Barry Richard J. | 10% Owner | Buy | P | 0.75 | 8,912 | 6,684 | 12,193,779 | 12.2 M to 12.2 M (+0.07 %) |
Jun 24 2010 | MBVX | MABVAX THERAPEUTIC ... | Barry Richard J. | 10% Owner | Buy | P | 0.75 | 10,449 | 7,837 | 12,184,867 | 12.2 M to 12.2 M (+0.09 %) |
Jun 23 2010 | MBVX | MABVAX THERAPEUTIC ... | Barry Richard J. | 10% Owner | Buy | P | 0.75 | 27,083 | 20,312 | 12,174,418 | 12.1 M to 12.2 M (+0.22 %) |
Jun 23 2010 | MBVX | MABVAX THERAPEUTIC ... | Barry Richard J. | 10% Owner | Buy | P | 0.75 | 90,217 | 67,663 | 12,147,335 | 12.1 M to 12.1 M (+0.75 %) |
Jun 17 2010 | MBVX | MABVAX THERAPEUTIC ... | WICK MICHAEL M | President, CEO and ... | Buy | P | 0.75 | 4,600 | 3,470 | 162,391 | 157.8 K to 162.4 K (+2.92 %) |
Jun 17 2010 | MBVX | MABVAX THERAPEUTIC ... | WICK MICHAEL M | President, CEO and ... | Buy | P | 0.77 | 200 | 154 | 157,791 | 157.6 K to 157.8 K (+0.13 %) |
Jun 17 2010 | MBVX | MABVAX THERAPEUTIC ... | WICK MICHAEL M | President, CEO and ... | Buy | P | 0.77 | 1,100 | 847 | 157,591 | 156.5 K to 157.6 K (+0.70 %) |
Jun 17 2010 | MBVX | MABVAX THERAPEUTIC ... | WICK MICHAEL M | President, CEO and ... | Buy | P | 0.77 | 983 | 755 | 156,491 | 155.5 K to 156.5 K (+0.63 %) |
Jun 17 2010 | MBVX | MABVAX THERAPEUTIC ... | WICK MICHAEL M | President, CEO and ... | Buy | P | 0.76 | 200 | 152 | 155,508 | 155.3 K to 155.5 K (+0.13 %) |
Jun 17 2010 | MBVX | MABVAX THERAPEUTIC ... | WICK MICHAEL M | President, CEO and ... | Buy | P | 0.76 | 1,300 | 986 | 155,308 | 154 K to 155.3 K (+0.84 %) |
Jun 17 2010 | MBVX | MABVAX THERAPEUTIC ... | WICK MICHAEL M | President, CEO and ... | Buy | P | 0.76 | 400 | 303 | 154,008 | 153.6 K to 154 K (+0.26 %) |
Jun 17 2010 | MBVX | MABVAX THERAPEUTIC ... | WICK MICHAEL M | President, CEO and ... | Buy | P | 0.76 | 100 | 76 | 153,608 | 153.5 K to 153.6 K (+0.07 %) |
Jun 17 2010 | MBVX | MABVAX THERAPEUTIC ... | WICK MICHAEL M | President, CEO and ... | Buy | P | 0.76 | 300 | 227 | 153,508 | 153.2 K to 153.5 K (+0.20 %) |
Jun 17 2010 | MBVX | MABVAX THERAPEUTIC ... | WICK MICHAEL M | President, CEO and ... | Buy | P | 0.76 | 100 | 76 | 153,208 | 153.1 K to 153.2 K (+0.07 %) |
Jun 17 2010 | MBVX | MABVAX THERAPEUTIC ... | WICK MICHAEL M | President, CEO and ... | Buy | P | 0.76 | 200 | 151 | 153,108 | 152.9 K to 153.1 K (+0.13 %) |
Jun 17 2010 | MBVX | MABVAX THERAPEUTIC ... | WICK MICHAEL M | President, CEO and ... | Buy | P | 0.76 | 300 | 227 | 152,908 | 152.6 K to 152.9 K (+0.20 %) |
Jun 17 2010 | MBVX | MABVAX THERAPEUTIC ... | WICK MICHAEL M | President, CEO and ... | Buy | P | 0.75 | 1,500 | 1,131 | 152,608 | 151.1 K to 152.6 K (+0.99 %) |
Jun 17 2010 | MBVX | MABVAX THERAPEUTIC ... | WICK MICHAEL M | President, CEO and ... | Buy | P | 0.75 | 8,300 | 6,258 | 151,108 | 142.8 K to 151.1 K (+5.81 %) |
Jun 17 2010 | MBVX | MABVAX THERAPEUTIC ... | WICK MICHAEL M | President, CEO and ... | Buy | P | 0.75 | 100 | 75 | 142,808 | 142.7 K to 142.8 K (+0.07 %) |
Jun 17 2010 | MBVX | MABVAX THERAPEUTIC ... | WICK MICHAEL M | President, CEO and ... | Buy | P | 0.75 | 1,600 | 1,206 | 142,708 | 141.1 K to 142.7 K (+1.13 %) |
Jun 17 2010 | MBVX | MABVAX THERAPEUTIC ... | WICK MICHAEL M | President, CEO and ... | Buy | P | 0.75 | 400 | 301 | 141,108 | 140.7 K to 141.1 K (+0.28 %) |
Jun 17 2010 | MBVX | MABVAX THERAPEUTIC ... | WICK MICHAEL M | President, CEO and ... | Buy | P | 0.75 | 500 | 377 | 140,708 | 140.2 K to 140.7 K (+0.36 %) |
Jun 17 2010 | MBVX | MABVAX THERAPEUTIC ... | WICK MICHAEL M | President, CEO and ... | Buy | P | 0.75 | 200 | 150 | 140,208 | 140 K to 140.2 K (+0.14 %) |
Jun 17 2010 | MBVX | MABVAX THERAPEUTIC ... | WICK MICHAEL M | President, CEO and ... | Buy | P | 0.75 | 7,617 | 5,713 | 140,008 | 132.4 K to 140 K (+5.75 %) |